NIMG-30. ASSESSING TREATMENT RESPONSE OF GLIOBLASTOMA TO AN HDAC INHIBITOR, BELINOSTAT (PXD101)

The current standard of care for glioblastoma (GBM; WHO grade IV glioma) is maximal safe resection followed by radiation therapy (RT) with concurrent and adjuvant chemotherapy. Despite this aggressive treatment, the median survival remains only 15 months. Thus, there is a need for better treatment o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Gurbani, Saumya, Sengupta, Soma, Voloschin, Alfredo, Liang, Zhongxing, Yoon, Younghyoun, Vega, Jose Enrique Velazquez, Holder, Chad A, Olson, Jeffrey J, Shu, Hui-Kuo, Shim, Hyunsuk
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692314/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.605
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados